Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Natanson

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
JAMA|September 19, 2008
Incomplete financial disclosure in a study of cell-free hemoglobin-based blood substitutes and risks of myocardial infarction and deathCharles Natanson
The American Journal of Bioethics : AJOB|January 4, 2020
Misrepresenting "Usual Care" in Research: An Ethical and Scientific ErrorRuth Macklin, Charles Natanson
The American Journal of Bioethics : AJOB|January 8, 2020
Response to Open Peer Commentaries on "Misrepresenting 'Usual Care' in Research: An Ethical and Scientific Error"Ruth Macklin, Charles Natanson
Critical Care Medicine|January 25, 2003
Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trialsPeter Q Eichacker, Charles Natanson
ACP Journal Club|May 3, 2002
Early goal-directed therapy reduced mortality and multiorgan dysfunction in severe sepsis or septic shockCharles Natanson, Robert L Danner
Intensive Care Medicine|August 25, 2010
Evaluating guidelines for critical care: a need for detailPeter Q Eichacker, Charles Natanson
Intensive Care Medicine|February 28, 2007
Increasing evidence that the risks of rhAPC may outweigh its benefitsPeter Q Eichacker, Charles Natanson
BMJ (Clinical Research Ed.)|January 15, 2025
Immunotherapies for sepsis and the impact of study designJohn H Powers, Charles Natanson
Mens Sana Monographs|October 21, 2011
Medical guidelines and performance measures: the need to keep them free of industry influencePeter Q Eichacker, Charles Natanson
Annals of Internal Medicine|November 21, 2012
Red blood cell transfusionHarvey G Klein, Charles Natanson
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
JAMA|September 19, 2008
Incomplete financial disclosure in a study of cell-free hemoglobin-based blood substitutes and risks of myocardial infarction and deathCharles Natanson
The American Journal of Bioethics : AJOB|January 4, 2020
Misrepresenting "Usual Care" in Research: An Ethical and Scientific ErrorRuth Macklin, Charles Natanson
The American Journal of Bioethics : AJOB|January 8, 2020
Response to Open Peer Commentaries on "Misrepresenting 'Usual Care' in Research: An Ethical and Scientific Error"Ruth Macklin, Charles Natanson
Critical Care Medicine|January 25, 2003
Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trialsPeter Q Eichacker, Charles Natanson
ACP Journal Club|May 3, 2002
Early goal-directed therapy reduced mortality and multiorgan dysfunction in severe sepsis or septic shockCharles Natanson, Robert L Danner
Intensive Care Medicine|August 25, 2010
Evaluating guidelines for critical care: a need for detailPeter Q Eichacker, Charles Natanson
Intensive Care Medicine|February 28, 2007
Increasing evidence that the risks of rhAPC may outweigh its benefitsPeter Q Eichacker, Charles Natanson
BMJ (Clinical Research Ed.)|January 15, 2025
Immunotherapies for sepsis and the impact of study designJohn H Powers, Charles Natanson
Mens Sana Monographs|October 21, 2011
Medical guidelines and performance measures: the need to keep them free of industry influencePeter Q Eichacker, Charles Natanson
Annals of Internal Medicine|November 21, 2012
Red blood cell transfusionHarvey G Klein, Charles Natanson
Pageof 12